FDA accelerated approval benefits glioblastoma

The Lancet Oncology

Volumn 11, Issue 12, 2010, Pages 1120-

  Cloughesy, Timothy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; LETTER; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DACARBAZINE; DRUG APPROVAL; GLIOBLASTOMA; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78649628169     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70269-2     Document Type: Letter

References (5)

1. Cohen MH, Shen YL, Keegan P, Pazdur R FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009, 14:1131-1138.
2. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999, 17:2762-2771.
3. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
4. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
5. When the evidence is weak, caution should be applied. Lancet Oncol 2010, 11:805. The Lancet Oncology.